Loading clinical trials...

SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma | Clinical Trials | Clareo Health

COMPLETEDPHASE2

SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma

A Phase 2 Study Of SU011248 In The Treatment Of Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma

NCT00089648•Pfizer

View on ClinicalTrials.gov

Summary

The purpose of this study is to test whether sunitinib (SU011248) has activity and is safe in patients with renal cell carcinoma (RCC) who have failed prior therapy with bevacizumab (Avastin) -based treatment.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Histologically proven renal cell carcinoma of clear cell histology with metastases
•Evidence of measurable disease
•Radiographic evidence of disease progression during or within 3 months of completion of bevacizumab-based treatment
•Prior radical or partial nephrectomy

Exclusion Criteria

•Prior treatment with any other anti-angiogenic therapy other than bevacizumab
•Prior systemic treatment for RCC \> 2 regimens
•History of or known brain metastases
•Serious acute or chronic illness or recent history of significant cardiac abnormality

Locations (11)

Pfizer Investigational Site

Duarte, California, United States

Pfizer Investigational Site

Pasadena, California, United States

Pfizer Investigational Site

San Francisco, California, United States

Pfizer Investigational Site

Chicago, Illinois, United States

Pfizer Investigational Site

Boston, Massachusetts, United States

Pfizer Investigational Site

Boston, Massachusetts, United States

Pfizer Investigational Site

Boston, Massachusetts, United States

Pfizer Investigational Site

Durham, North Carolina, United States

Pfizer Investigational Site

Cleveland, Ohio, United States

Pfizer Investigational Site

Nashville, Tennessee, United States

Key Dates

Start Date

December 1, 2004

Primary Completion Date

January 1, 2007

Completion Date

March 1, 2008

Last Updated

January 12, 2010

Enrollment

ACTUAL participants

Conditions

Carcinoma, Renal Cell

Interventions

Sunitinib

DRUG

A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

NCT07227415

Carcinoma, Renal CellAdvanced Renal Cell Carcinoma+11 more

View study

RECRUITINGPHASE2

Autologous Dendritic Cell Vaccine in Kidney Cancer

NCT05127824

Carcinoma, Renal Cell

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 12, 2010Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma

Inclusion Criteria

Exclusion Criteria

A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

Autologous Dendritic Cell Vaccine in Kidney Cancer

A Study of Oncobax®-AK in Patients With Advanced Solid Tumors

A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma

A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment